These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15801851)

  • 1. From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
    Gerona-Navarro G; Pérez de Vega MJ; García-López MT; Andrei G; Snoeck R; De Clercq E; Balzarini J; González-Muñiz R
    J Med Chem; 2005 Apr; 48(7):2612-21. PubMed ID: 15801851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and anti-HCMV activity of 1-acyl-beta-lactams and 1-acylazetidines derived from phenylalanine.
    Gerona-Navarro G; Pérez de Vega MJ; García-López MT; Andrei G; Snoeck R; Balzarini J; De Clercq E; González-Muñiz R
    Bioorg Med Chem Lett; 2004 May; 14(9):2253-6. PubMed ID: 15081019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.
    Borthwick AD; Davies DE; Ertl PF; Exall AM; Haley TM; Hart GJ; Jackson DL; Parry NR; Patikis A; Trivedi N; Weingarten GG; Woolven JM
    J Med Chem; 2003 Oct; 46(21):4428-49. PubMed ID: 14521407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptidomimetic inhibitors of the human cytomegalovirus protease.
    Ogilvie W; Bailey M; Poupart MA; Abraham A; Bhavsar A; Bonneau P; Bordeleau J; Bousquet Y; Chabot C; Duceppe JS; Fazal G; Goulet S; Grand-Maître C; Guse I; Halmos T; Lavallée P; Leach M; Malenfant E; O'Meara J; Plante R; Plouffe C; Poirier M; Soucy F; Yoakim C; Déziel R
    J Med Chem; 1997 Dec; 40(25):4113-35. PubMed ID: 9406601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. beta-Lactam derivatives as inhibitors of human cytomegalovirus protease.
    Yoakim C; Ogilvie WW; Cameron DR; Chabot C; Guse I; Haché B; Naud J; O'Meara JA; Plante R; Déziel R
    J Med Chem; 1998 Jul; 41(15):2882-91. PubMed ID: 9667976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of translactam HCMV protease inhibitors as potent antivirals.
    Borthwick AD
    Med Res Rev; 2005 Jul; 25(4):427-52. PubMed ID: 15789440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease.
    Flynn DL; Becker DP; Dilworth VM; Highkin MK; Hippenmeyer PJ; Houseman KA; Levine LM; Li M; Moormann AE; Rankin A; Toth MV; Villamil CI; Wittwer AJ; Holwerda BC
    Drug Des Discov; 1997 May; 15(1):3-15. PubMed ID: 9332827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality.
    Borthwick AD; Crame AJ; Ertl PF; Exall AM; Haley TM; Hart GJ; Mason AM; Pennell AM; Singh OM; Weingarten GG; Woolven JM
    J Med Chem; 2002 Jan; 45(1):1-18. PubMed ID: 11754575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel series of inhibitors of human cytomegalovirus primase.
    Cushing TD; Adrian J; Chen X; DiMaio H; Doughan B; Flygare J; Liang L; Mayorga V; Miao S; Mellon H; Peterson MG; Powers JP; Spector F; Stein C; Wright M; Xu D; Ye Q; Jaen J
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4879-83. PubMed ID: 16814545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antiviral activity of monobactams inhibiting the human cytomegalovirus protease.
    Ogilvie WW; Yoakim C; Dô F; Haché B; Lagacé L; Naud J; O'Meara JA; Déziel R
    Bioorg Med Chem; 1999 Aug; 7(8):1521-31. PubMed ID: 10482444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the covalent modification of the catalytic triad of human cytomegalovirus protease by pseudo-reversible beta-lactam inhibitors and a peptide chloromethylketone.
    Haley TM; Angier SJ; Borthwick AD; Montgomery DS; Purvis IJ; Smart DH; Bessant C; Van Wely C; Hart GJ
    J Mass Spectrom; 1998 Dec; 33(12):1246-55. PubMed ID: 9875526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase.
    Loregian A; Coen DM
    Chem Biol; 2006 Feb; 13(2):191-200. PubMed ID: 16492567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Lactam derivatives as enzyme inhibitors: N-substituted derivatives of (S)-4-oxoazetidine-2-carboxylate as inhibitors of elastase and papain.
    Achilles K; Schneider M; Schirmeister T; Otto HH
    Pharmazie; 2000 Nov; 55(11):798-802. PubMed ID: 11125993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
    Nair LG; Sannigrahi M; Bogen S; Pinto P; Chen KX; Prongay A; Tong X; Cheng KC; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem Lett; 2010 Jan; 20(2):567-70. PubMed ID: 20004570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism.
    McGuigan C; Pathirana RN; Snoeck R; Andrei G; De Clercq E; Balzarini J
    J Med Chem; 2004 Mar; 47(7):1847-51. PubMed ID: 15027877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
    Bondada L; Rondla R; Pradere U; Liu P; Li C; Bobeck D; McBrayer T; Tharnish P; Courcambeck J; Halfon P; Whitaker T; Amblard F; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6325-30. PubMed ID: 24135727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability.
    Borthwick AD; Exall AM; Haley TM; Jackson DL; Mason AM; Weingarten GG
    Bioorg Med Chem Lett; 2002 Jul; 12(13):1719-22. PubMed ID: 12067545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent beta-lactam inhibitors of human cytomegalovirus protease.
    Yoakim C; Ogilvie WW; Cameron DR; Chabot C; Grand-Maître C; Guse I; Haché B; Kawai S; Naud J; O'Meara JA; Plante R; Déziel R
    Antivir Chem Chemother; 1998 Sep; 9(5):379-87. PubMed ID: 9875391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Charge modification of plasma and milk proteins results in antiviral active compounds.
    Swart PJ; Harmsen MC; Kuipers ME; Van Dijk AA; Van Der Strate BW; Van Berkel PH; Nuijens JH; Smit C; Witvrouw M; De Clercq E; de Béthune MP; Pauwels R; Meijer DK
    J Pept Sci; 1999 Dec; 5(12):563-76. PubMed ID: 10628656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
    de Castro S; Peromingo MT; Naesens L; Andrei G; Snoeck R; Balzarini J; Velázquez S; Camarasa MJ
    J Med Chem; 2008 Sep; 51(18):5823-32. PubMed ID: 18707089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.